vs
Astrana Health, Inc.（ASTH）与德康医疗（DXCM）财务数据对比。点击上方公司名可切换其他公司
德康医疗的季度营收约是Astrana Health, Inc.的1.3倍（$1.3B vs $950.5M），德康医疗净利率更高（21.2% vs 0.7%，领先20.5%），Astrana Health, Inc.同比增速更快（42.9% vs 21.6%），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs 12.0%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
ASTH vs DXCM — 直观对比
营收规模更大
DXCM
是对方的1.3倍
$950.5M
营收增速更快
ASTH
高出21.3%
21.6%
净利率更高
DXCM
高出20.5%
0.7%
两年增速更快
ASTH
近两年复合增速
12.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.3B |
| 净利润 | $6.6M | $267.3M |
| 毛利率 | — | 62.9% |
| 营业利润率 | 1.9% | 25.6% |
| 净利率 | 0.7% | 21.2% |
| 营收同比 | 42.9% | 21.6% |
| 净利润同比 | 184.4% | 153.6% |
| 每股收益（稀释后） | $0.12 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHDXCM
| Q1 26 | — | $1.3B | ||
| Q4 25 | $950.5M | $1.3B | ||
| Q3 25 | $956.0M | $1.2B | ||
| Q2 25 | $654.8M | $1.2B | ||
| Q1 25 | $620.4M | $1.0B | ||
| Q4 24 | $665.2M | $1.1B | ||
| Q3 24 | $478.7M | $994.2M | ||
| Q2 24 | $486.3M | $1.0B |
净利润ASTHDXCM
| Q1 26 | — | $267.3M | ||
| Q4 25 | $6.6M | $267.3M | ||
| Q3 25 | $373.0K | $283.8M | ||
| Q2 25 | $9.4M | $179.8M | ||
| Q1 25 | $6.7M | $105.4M | ||
| Q4 24 | $-7.8M | $151.7M | ||
| Q3 24 | $16.1M | $134.6M | ||
| Q2 24 | $19.2M | $143.5M |
毛利率ASTHDXCM
| Q1 26 | — | 62.9% | ||
| Q4 25 | — | 62.9% | ||
| Q3 25 | — | 60.5% | ||
| Q2 25 | — | 59.5% | ||
| Q1 25 | — | 56.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 59.7% | ||
| Q2 24 | — | 62.4% |
营业利润率ASTHDXCM
| Q1 26 | — | 25.6% | ||
| Q4 25 | 1.9% | 25.6% | ||
| Q3 25 | 2.0% | 20.1% | ||
| Q2 25 | 3.1% | 18.4% | ||
| Q1 25 | 3.3% | 12.9% | ||
| Q4 24 | 0.1% | 17.0% | ||
| Q3 24 | 5.9% | 15.3% | ||
| Q2 24 | 6.2% | 15.7% |
净利率ASTHDXCM
| Q1 26 | — | 21.2% | ||
| Q4 25 | 0.7% | 21.2% | ||
| Q3 25 | 0.0% | 23.5% | ||
| Q2 25 | 1.4% | 15.5% | ||
| Q1 25 | 1.1% | 10.2% | ||
| Q4 24 | -1.2% | 13.6% | ||
| Q3 24 | 3.4% | 13.5% | ||
| Q2 24 | 3.9% | 14.3% |
每股收益（稀释后）ASTHDXCM
| Q1 26 | — | $0.67 | ||
| Q4 25 | $0.12 | $0.67 | ||
| Q3 25 | $0.01 | $0.70 | ||
| Q2 25 | $0.19 | $0.45 | ||
| Q1 25 | $0.14 | $0.27 | ||
| Q4 24 | $-0.14 | $0.37 | ||
| Q3 24 | $0.33 | $0.34 | ||
| Q2 24 | $0.40 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $917.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $779.3M | $2.7B |
| 总资产 | $2.2B | $6.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASTHDXCM
| Q1 26 | — | $917.7M | ||
| Q4 25 | $429.5M | $917.7M | ||
| Q3 25 | $463.4M | $1.8B | ||
| Q2 25 | $342.1M | $1.2B | ||
| Q1 25 | $260.9M | $904.9M | ||
| Q4 24 | $290.8M | $606.1M | ||
| Q3 24 | $350.3M | $621.2M | ||
| Q2 24 | $327.7M | $939.2M |
股东权益ASTHDXCM
| Q1 26 | — | $2.7B | ||
| Q4 25 | $779.3M | $2.7B | ||
| Q3 25 | $775.5M | $2.7B | ||
| Q2 25 | $765.5M | $2.6B | ||
| Q1 25 | $745.4M | $2.3B | ||
| Q4 24 | $712.7M | $2.1B | ||
| Q3 24 | $704.6M | $2.0B | ||
| Q2 24 | $678.9M | $2.4B |
总资产ASTHDXCM
| Q1 26 | — | $6.3B | ||
| Q4 25 | $2.2B | $6.3B | ||
| Q3 25 | $2.2B | $7.5B | ||
| Q2 25 | $1.4B | $7.3B | ||
| Q1 25 | $1.3B | $6.8B | ||
| Q4 24 | $1.4B | $6.5B | ||
| Q3 24 | $1.3B | $6.4B | ||
| Q2 24 | $1.3B | $6.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | — |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | — |
| 自由现金流率自由现金流/营收 | -0.6% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | — |
8季度趋势，按日历期对齐
经营现金流ASTHDXCM
| Q1 26 | — | — | ||
| Q4 25 | $-2.9M | $294.0M | ||
| Q3 25 | $10.0M | $659.9M | ||
| Q2 25 | $90.9M | $303.0M | ||
| Q1 25 | $16.6M | $183.8M | ||
| Q4 24 | $-10.9M | $301.4M | ||
| Q3 24 | $34.0M | $199.5M | ||
| Q2 24 | $23.2M | $279.4M |
自由现金流ASTHDXCM
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | $192.1M | ||
| Q3 25 | $7.4M | $579.4M | ||
| Q2 25 | $89.5M | $208.9M | ||
| Q1 25 | $13.6M | $96.8M | ||
| Q4 24 | $-13.5M | $176.8M | ||
| Q3 24 | $31.7M | $88.3M | ||
| Q2 24 | $20.4M | $213.3M |
自由现金流率ASTHDXCM
| Q1 26 | — | — | ||
| Q4 25 | -0.6% | 15.3% | ||
| Q3 25 | 0.8% | 47.9% | ||
| Q2 25 | 13.7% | 18.1% | ||
| Q1 25 | 2.2% | 9.3% | ||
| Q4 24 | -2.0% | 15.9% | ||
| Q3 24 | 6.6% | 8.9% | ||
| Q2 24 | 4.2% | 21.2% |
资本支出强度ASTHDXCM
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 8.1% | ||
| Q3 25 | 0.3% | 6.7% | ||
| Q2 25 | 0.2% | 8.1% | ||
| Q1 25 | 0.5% | 8.4% | ||
| Q4 24 | 0.4% | 11.2% | ||
| Q3 24 | 0.5% | 11.2% | ||
| Q2 24 | 0.6% | 6.6% |
现金转化率ASTHDXCM
| Q1 26 | — | — | ||
| Q4 25 | -0.44× | 1.10× | ||
| Q3 25 | 26.69× | 2.33× | ||
| Q2 25 | 9.65× | 1.69× | ||
| Q1 25 | 2.48× | 1.74× | ||
| Q4 24 | — | 1.99× | ||
| Q3 24 | 2.11× | 1.48× | ||
| Q2 24 | 1.21× | 1.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
DXCM
暂无分部数据
